Article
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
JCI insight - 8 Mar 2018
Jacoby Meagan A, Duncavage Eric J, Chang Gue Su, Miller Christopher A, Shao Jin, Elliott Kevin, Robinson Joshua, Fulton Robert S, Fronick Catrina C, O'Laughlin Michelle, Heath Sharon E, Pusic Iskra, Welch John S, Link Daniel C, DiPersio John F, Westervelt Peter, Ley Timothy J, Graubert Timothy A, Walter Matthew J
Abstract excerpt
Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for myelodysplastic syndromes (MDS), but patients who relapse after transplant have poor outcomes. In order to understand the contribution of tumor clonal evolution to disease progression,we applied exome and error-corrected targeted sequencing coupled with copy number analysis to comprehensively define changes in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.